InnoCare Pharma (HKG: 9969; SHA: 688428) and Keymed Biosciences Inc., (HKG: 2162) have announced a significant milestone in their joint development of ICP-B02 (CM355), a bispecific antibody (BsAb) targeting CD20 and CD3. The first subcutaneous injection administration has been successfully administered to a Chinese patient, marking a new route of administration in addition to the intravenous infusion mode for this clinical trial.
ICP-B02’s Mechanism of Action and Clinical Trial Significance
ICP-B02 is currently under clinical trials in China for CD20+ B-cell hematoma. The bispecific antibody specifically binds to CD20 positive target cells and CD3 positive T cells, recruiting immune T cells around the target cells. This interaction activates T cells and induces T cell-mediated tumor cell killing (TDCC), leading to the destruction of the target cells. The ability to administer ICP-B02 via subcutaneous injection, in addition to intravenous infusion, could offer increased flexibility and convenience for patients and healthcare providers.
The Clinical Trial’s Potential Impact
The initiation of this clinical trial and the first subcutaneous injection administration are important steps in the development of ICP-B02. This trial aims to evaluate the safety, tolerability, and efficacy of the new administration route, which could potentially improve patient compliance and treatment outcomes. The collaboration between InnoCare Pharma and Keymed Biosciences highlights the ongoing commitment to advancing innovative immunotherapies for the treatment of CD20+ B-cell hematoma.-Fineline Info & Tech
